Modulators of calcium release-activated calcium channel

Patent metadata

Field	Value
Publication number	US-10246450-B2
Application number	US-201815892229-A
Country	US
Kind code	B2
Filing date	Feb 8, 2018
Priority date	Oct 8, 2009
Publication date	Apr 2, 2019
Grant date	Apr 2, 2019

Abstract

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

First claim

We claim:

1. A method of treating an autoimmune disorder comprising the step of administering to a subject in need thereof an effective amount of a compound of formula

or a pharmaceutically acceptable salt thereof, wherein
Ring Hy represents

optionally substituted with R′″;
R 1 and R 2 are the same or different and are independently selected from CH 3 , CH 2 F, CHF 2 , CF 3 , substituted or unsubstituted C (3-5) cycloalkyl, CH 2 —OR a , CH 2 —NR a R b , CN and COOH with the proviso that:
a) both R 1 and R 2 at the same time do not represent CF 3 ,
b) both R 1 and R 2 at the same time do not represent CH 3 ,
c) when R 1 is CF 3 then R 2 is not CH 3 ; and
d) when R 1 is CH 3 then R 2 is not CF 3 ;

Ring Ar represents:

L 1 and L 2 together represent NH—C(═O)—;
A is absent;
R′″ is selected from hydrogen, hydroxy, cyano, halogen, —OR a , —COOR a , —S(═O) q —R a , —NR a R b , C(═X)—R a , substituted or unsubstituted C (1-6) alkyl group, substituted or unsubstituted C (1-6) alkenyl, substituted or unsubstituted C (1-6) alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl;
each occurrence of X is independently selected from O, S and —NR a ;
Cy is selected from monocyclic substituted or unsubstituted cycloalkyl group, monocyclic substituted or unsubstituted aryl; and substituted or unsubstituted pyridyl;
each occurrence of R a and R b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR c , —S(═O) q —R c , —NR c R d , —C(═Y)—R c , —CR c R d —C(═Y)—R c , —CR c R d —Y—CR c R d —, —C(═Y)—NR c R d —, —NRR d —C(═Y)—NR c R d —, —S(═O) q —NR c R d —, —NR c R d —S(═O) q —NR c R d —, —NR c R d —NR c R d —, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R a and R b are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR c and S;
each occurrence of R c and R d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R c and/or R d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;
each occurrence of Y is selected from O, S and —NR a ; and
each occurrence of q independently represents 0, 1 or 2;
wherein the autoimmune disorder is chronic obstructive pulmonary disease, inflammatory bowel disease, allergic rhinitis, multiple sclerosis, psoriasis, Crohn's disease, colitis, ulcerative colitis, arthritis, bone diseases associated with increased bone resorption, or chronic obstructive airway disease.

2. The method of claim 1 , wherein the autoimmune disorder is multiple sclerosis, chronic obstructive pulmonary disease, chronic obstructive airway disease, or psoriasis.

3. The method of claim 1 , wherein the subject is a human subject.

4. The method of claim 2 , wherein the subject is a human subject.

5. A method of modulating store-operated calcium (SOC) channel activity comprising contacting the SOC channel complex, or portion thereof, with a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

6. A method of modulating calcium release activated calcium channel (CRAC) activity in a mammal comprising administering to the mammal a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

7. A method of inhibiting store-operated calcium entry (SOCE) activation of nuclear factor of activated T cells (NFAT) in a mammal comprising administering to the mammal a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

8. A method of decreasing cytokine release by inhibiting the SOCE activation of NFAT in a mammal comprising administering to the mammal a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

9. A method of inhibiting immune cell activation comprising administering to an immune cell a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

10. A method of inhibiting T-cell and/or B-cell proliferation in response to an antigen, comprising administering to a T-cell and/or B-cell cell a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

11. A method of inhibiting cytokine production in a cell comprising administering to the cell a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein the cytokine is selected from IL-2, IL-4, IL-5, IL-13, GM-CSF, IFN-γ, TNFα, and combinations thereof.

13. A method of modulating an ion channel in a cell, wherein the ion channel is involved in immune cell activation, comprising administering to the cell a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein the ion channel is a Ca 2+ -release-activated Ca 2+ channel (CRAC).

15. A method of reducing an inflammation in a subject in need thereof comprising administering to the subject an effective amount of a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

16. A method of treating an autoimmune disorder comprising the step of administering to a subject in need thereof an effective amount of a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof, wherein the autoimmune disorder is chronic obstructive pulmonary disease, inflammatory bowel disease, allergic rhinitis, asthma, multiple sclerosis, ps

Assignees

• Rhizen Pharmaceuticals Sa

Inventors

• Muthuppalaniappan Meyyappan
• Viswanadha Srikant
• Merikapudi Gayatri S
• Vakkalanka Swaroop K

Classifications

• C12N2500/46

  Amines, e.g. putrescine · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title

• C07D417/10 Primary

  linked by a carbon chain containing aromatic rings · CPC title

• C07D413/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D403/10

  linked by a carbon chain containing aromatic rings · CPC title